抗感染药物临床试验中的半盲优效性检验
本文提出一种基于随机临床试验的半盲优效性检验,用于证明新抗感染药B优于对照药A。该方法利用分别预测A和B获益的基线协变量XA和XB,通过反应面模型在最可能显示优效的(XA,XB)点进行检验,并采用新型半盲伪似然估计。模拟和实例表明,该估计比仅基于混合盲似然更优,且几乎等同于完全盲数据估计。
要点
- 半盲伪似然估计性能接近完全盲数据,优于仅用混合盲似然。
- 检验可同时用于非劣效试验的试验敏感性验证和个体化药物选择。
- 若半盲检验拒绝,可用逐点置信区间识别获益患者。
核心结论
- 半盲优效性检验可用于证明新抗感染药B优于对照药A,并支持个体化用药选择。
- 半盲伪似然估计几乎等同于完全盲数据估计,且优于仅基于混合盲似然的估计。
研究设计与样本
- 基于随机临床试验,提出半盲优效性检验,利用基线协变量XA和XB及反应面模型。
- 采用新型半盲伪似然进行估计,并用置换方法进行检验。
- 通过实例和模拟比较新检验与其他方法。
主要发现
- 半盲伪似然估计比仅基于混合盲似然的估计好得多,且几乎表现为基于完全盲数据的估计。
- 当XB变异很小时,开发了仅使用XA的类似单变量方法。
- 若半盲检验拒绝,逐点置信区间可用于识别从药物B获益的患者。
临床怎么用
- 可用于非劣效试验中证明试验敏感性。
- 可严谨地为个体患者量身定制药物选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This paper introduces a test of superiority of new anti-infective drug B over comparator drug A based on a randomized clinical trial. This test can be used to demonstrate assay (trial) sensitivity for noninferiority trials and rigorously tailor drug choice for individual patients. Our approach uses specialized baseline covariates XA ,XB , which should predict the benefits of drug A and drug B, respectively. Using a response surface model for the treatment effect, we test for superiority at the (XA ,XB ) point that is most likely to show superiority. We identify this point based on estimates from a novel half-blind pseudo likelihood, where we augment a blinded likelihood (mixed over the treatment indicator) with likelihoods for the overall success rates for drug A and drug B (mixed over XA ,XB ). The augmentation results in much better estimates than those based on the mixed blinded likelihood alone but, interestingly, the estimates almost behave as if they were based on fully blinded data. We also develop an analogous univariate method using XA for settings where XB has little variation. Permutation methods are used for testing. If the "half-blind" test rejects, pointwise confidence interval can be used to identify patients who would benefit from drug B. We compare the new tests to other methods with an example and via simulations.
引用
- Follmann D, Brittain E, Lumbard K, et al. Half blind superiority tests for clinical trials of anti-infective drugs. Stat Med. 2018. PMID: 30203497. doi:10.1002/sim.7954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。